13th World ADC San Diego 2022
Start Date: 2022-09-06
End Date: 2022-09-09
Time: 10:00 am to 4:00 pm
Phone: + 1 415 735 3289
Running for the first time in-person since 2019, the hotly anticipated 13th World ADC San Diego is back, bigger and better than ever before.
With a continued dedication to curating scientific insights and transformative lessons to maximizing the clinical therapeutic index of your ADC, this year’s meeting delves further into the resurgence of ADCs being used as combination therapies, next generation payloads, and how to evolve your manufacturing processes in this fast-paced and ever-evolving field.
As your global one stop shop for antibody drug conjugates from early discovery to late phase manufacturing, join AstraZeneca, Genentech, Mersana Therapeutics, Sutro Biopharma, Daiichi Sankyo and many more to gain updates from the dynamic nonclinical and clinical environment. Address shared challenges of using biomarkers in preclinical and clinical development, debate the optimal structure of payloads, uncover approaches to advancing novel ADCs into the clinic and discover the promise of ADCs targeting Folate Receptor Alpha.
This is your ultimate platform to meet face-to-face with 600+ pioneers at the forefront of ADC R and D and foster vital scientific exchange and communication to propel these life-saving therapeutics to more patients now.
Speakers: Jagath Reddy Junutula, President, Chief Executive Officer and Co-Founder, Aarvik Therapeutics, Andy Vo, Senior Scientist, Computational Toxicology, AbbVie, Rajeev Menon, Senior Director and Senior Research Fellow, AbbVie, Regina Reilly, Research Fel,low, Oncology Discovery Research, AbbVie, Sabra Hanspal, Senior Scientist, AbbVie Contract Manufacturing, Sang Jeon Chung, Chief Executive Officer and Founder, AbTis, Nicolas Camper, Senior Director, Chemistry, Abzena, Ying Wang, Executive Medical Director, ADC Therapeutics, Akira Chiba, Senior Principal Researcher, Ajinomoto Bio- Pharma Services, David Mills, Director, Preclinical Science, Ambrx, Ying Buechler, Senior Vice President, Development, Ambrx, Francesco Bonardi, Director, Bioanalysis, Ardena, Anton Rosenbaum, Director, Integrated Bioanalytics, AstraZeneca, Elaine Hurt, Senior Director, Bioscience, AstraZeneca, Jay Harper, Director, Tumor Targeted Delivery, AstraZeneca, Marlon Rebelatto, Executive Director, Translational Pathology, AstraZeneca, Puja Sapra, Senior Vice President, Head R and D Biologics Engineering and Head Oncology Targeted Delivery, AstraZeneca, Weiping Shao, Senior Group Director, AstraZeneca, Yue Huang, Associate Director, Bioanalytical, AstraZeneca, John Lambert, Consultant, Attager Consulting, Ramana Doppalapudi, Vice President, Chemistry, Avidity Biosciences, Ahmed Bassyouni, Independent Consultant, Bassyouni Consulting, Jia He, Senior Research Analyst, Beacon Targeted Therapies, Nathan Tumey, Associate Professor, Binghampton University, Rakesh Dixit, Chief Executive Officer, Bionavigen, Gerhard Frey, Vice President, Technology Development, BioAtla, Srikanth Kotapati, Senior Principal Scientist, Bristol-Myers Squibb, Shelley Ackerman, Associate Director, Bolt Biotherapeutics, Giorgio Salciarni, Senior Manager, Technical Business Development, BSP Pharmaceuticals, Ayo Ogunkoya, Senior Research Scientist, Chemical Biology, Catalent Biologics, Jarrod Longcor, Chief Operating Officer, Cellectar Biosciences, Speaker TBC, Daiichi Sankyo, Sadhna Shankar, Vice President, Clinical Development Oncology, Eisai, Gregory Adams, Chief Scientific Officer, Elucida Oncology, David Conlon, Consultant, Ex-Daiichi Sankyo, Yuyi Shen, Ex-Director, Process Development and Manufacturing, Ex-Bolt Biotherapeutics, Ian Schwartz, Director, Bioconjugation Process Development, Exelixis, Inna Vainshtein, Senior Director, Bioanalysis, Exelixis, Ben-Quan Shen, Senior Fellow, Genentech, Chunze Li, Executive Director and Senior Principal Scientist, Head, Oncology Clinical Pharmacology, Genentech, Donglu Zhang, Senior Fellow, Genentech, Gail Diane Lewis, Principal Scientist, Genentech, Jamie Hirata, Global Development Leader, Genentech, Rachel Hendricks, Technical Development Scientist, Genentech, Thomas Pillow, Principal Scientist, Genentech, Derek Langesla, Senior Research Scientist, Gilead Sciences, Sandhya Girish, Vice President, Clinical Pharmacology, Gilead Sciences, Brian Clark, Principal, GMP Operations Consulting LLC, Speaker TBC GlycoT Therapeutics, Andreas Pahl, Chief Scientific Officer, Heidelberg Pharma Research, Marisa Schmitt, Group Leader, Bioanalytics, Heidelberg Pharma Research, Ed Ha, Head, ADC Innovation, Iksuda, Michael Method, Executive Medical Director, ImmunoGen, Mimi Huizinga, Senior Vice President, Medical Affairs, ImmunoGen, Patrick Zweidler- McKay, Executive Medical Director, ImmunoGen, Nathan Alves, Director, Translation Research, Indiana University, Tae Kyo Park, Chief Executive Officer, IntoCell, Sagit Hindi, Associate Director, CMC Regulatory DDO, Biologics Department, Johnson and Johnson, Shalom Goldberg, Senior Principal Scientist, Johnson and Johnson, Xiangyang Tan, Chief Scientific Officer, Klus Pharma, Jeiwook Chae, Chief Business Development Officer, LegoChem Biosciences, Ernest Kovacs, Director, Bioconjugation, Levena Biopharma, Speaker TBC, Ligand Pharmaceuticals, Patrick Dennler, Lab Head, Scientific Specialist, Lonza, Sonia Jain, Research Associate, Mayo Clinic, Timothy Yap, Associate Professor, University of Texas MD Anderson Cancer Center, Emmett Schmidt, Vice President, External Collaborations, Merck and Co., Hong Ren, Principal Scientist, Merck and Co., Jianzhog Wen, Associate Principal Scientist, Merck and Co., Paul Bulger, Director, Analytical Research and Development, Merck and Co., Radhika Balasubramani, Director, ADC, Global Technical Operations, Merck and Co., Fu Li, Director, Biology, Mersana Therapeutics, Lei Zhu, Head, Chemical Process and Supply Development, Mersana Therapeutics, Ling Xu, Fellow, Mersana Therapeutics, Tim Lowinger, Chief Scientific and Technology Officer, Mersana Therapeutics, Gang Yao, Director, Head of Novel Modalities R and D, Millipore Sigma, Lisa McDermott, Director, Process and Analytical Development, Millipore Sigma, Roger Beerli, Chief Scientific Officer, NBE-Therapeutics, Julien Dugal-Tessier, Director, Innovative Chemistry and Bioconjugation, NJ Biopharmaceuticals, Naresh Jain, Chief Executive Officer, NJ Biopharmaceuticals, Yuki Matsuno, Researcher, NOF Corporation, Bertrand Cottineau, Group Head, R and D, Novasep, Melanie Derde, Head, Analytical Bioconjugation, Novasep, Michael Jones, Research, Fellow Pfizer, Samuele Cazzamalli, Head, Small Molecule Therapeutics, Philochem, Conor Barry, Head, Development, Piramal Pharma Solutions, Vitor Sousa, R and D Biological Senior Manager, PROVEO, Amy Han, Director, Solid Tumor Targeted Therapies, Regeneron, John DaSilva, Associate Director, Oncology and Immuno Oncology, Regeneron, Thomas Nittoli, Senior Director, R and D Chemistry, Regeneron, Robert Sussman, Managing Director, SafeBridge Regulatory and Life Sciences Group, Hannes Landmann, Product Manager, Crossflow Systems, Sartorius, Marvin Machava, Process Engineering, Downstream Development, Sartorius, Betsy Gray, Principal Scientist, Therapeutic Discovery, Seagen, Chris Lieske, Senior Scientist, Seagen, Emily Stevens, Medical Director, Clinical Biomarkers and Bioinformatics, Seagen, Lindsay Fay, Scientist, Formulation and Drug Product Development, Seagen
Organized by : Hanson Wade Tel : + 1 415 735 3289
About the Organizers :
Drug Developer - Conference Only (2 Day Pass): USD 2899.00,
Drug Developer - Conference + Seminar Day (3 Day Pass): USD 3898.00,
Drug Developer - Conference + Seminar and Workshop Day (4 Day Pass): USD 4897.00,
Solution Provider - Conference Only (2 Day Pass): USD 3499.00,
Solution Provider - Conference + Seminar Day (3 Day Pass): USD 4598.00,
Solution Provider - Conference + Seminar and Workshop Day (4 Day Pass): USD 5697.00,
Academic Provider - Conference Only (2 Day Pass): USD 2499.00,
Academic Provider - Seminar Day (3 Day Pass): USD 3298.00,
Academic Provider - Conference + Seminar and Workshop Day (4 Day Pass): USD 4097.00